TIMI bleeding criteria

WikiDoc Resources for TIMI bleeding criteria
Articles
Most recent articles on TIMI bleeding criteria Most cited articles on TIMI bleeding criteria Review articles on TIMI bleeding criteria Articles on TIMI bleeding criteria in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on TIMI bleeding criteria Images of TIMI bleeding criteria Photos of TIMI bleeding criteria Podcasts & MP3s on TIMI bleeding criteria Videos on TIMI bleeding criteria
Evidence Based Medicine
Cochrane Collaboration on TIMI bleeding criteria Bandolier on TIMI bleeding criteria TRIP on TIMI bleeding criteria
Clinical Trials
Ongoing Trials on TIMI bleeding criteria at Clinical Trials.gov Trial results on TIMI bleeding criteria Clinical Trials on TIMI bleeding criteria at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on TIMI bleeding criteria NICE Guidance on TIMI bleeding criteria NHS PRODIGY Guidance FDA on TIMI bleeding criteria CDC on TIMI bleeding criteria
Books
Books on TIMI bleeding criteria
News
TIMI bleeding criteria in the news Be alerted to news on TIMI bleeding criteria News trends on TIMI bleeding criteria
Commentary
Blogs on TIMI bleeding criteria
Definitions
Definitions of TIMI bleeding criteria
Patient Resources / Community
Patient resources on TIMI bleeding criteria Discussion groups on TIMI bleeding criteria Patient Handouts on TIMI bleeding criteria Directions to Hospitals Treating TIMI bleeding criteria Risk calculators and risk factors for TIMI bleeding criteria
Healthcare Provider Resources
Symptoms of TIMI bleeding criteria Causes & Risk Factors for TIMI bleeding criteria Diagnostic studies for TIMI bleeding criteria Treatment of TIMI bleeding criteria
Continuing Medical Education (CME)
CME Programs on TIMI bleeding criteria
International
TIMI bleeding criteria en Espanol TIMI bleeding criteria en Francais
Business
TIMI bleeding criteria in the Marketplace Patents on TIMI bleeding criteria
Experimental / Informatics
List of terms related to TIMI bleeding criteria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria , , , is one of the most frequently used classifications in the cardiovascular trials. These criteria were developed during early TIMI trials to define minor and major hemorrhagic episodes in patients of ST segment elevation MI (STEMI) treated with a fibrinolytic drug and have been there for 30 years. It was mainly dependent on laboratory values like decrease in hemoglobin or hematocrit values. It has been modified over time and the most recent version is shown below.

TIMI Bleeding Criteria

“

Non-CABG related bleeding: 1. Major Any intracranial bleeding (excluding microhemorrhages <10 mm evident only on gradient-echo MRI) Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or a ≥15% absolute decrease in haematocrit Fatal bleeding (bleeding that directly results in death within 7 d) 2. Minor Clinically overt (including imaging), resulting in hemoglobin drop of 3 to <5 g/dL or ≥10% decrease in haematocrit No observed blood loss: ≥4 g/dL decrease in the haemoglobin concentration or ≥12% decrease in haematocrit Any overt sign of hemorrhage that meets one of the following criteria and does not meet criteria for a major or minor bleeding event, as defined above Requiring intervention (medical practitioner-guided medical or surgical treatment to stop or treat bleeding, including temporarily or permanently discontinuing or changing the dose of a medication or study drug) Leading to or prolonging hospitalization Prompting evaluation (leading to an unscheduled visit to a healthcare professional and diagnostic testing, either laboratory or imaging) 3. Minimal Any overt bleeding event that does not meet the criteria above Any clinically overt sign of haemorrhage (including imaging) associated with a <3 g/dL decrease in haemoglobin concentration or <9% decrease in haematocrit Bleeding in the setting of CABG: Fatal bleeding (bleeding that directly results in death) Perioperative intracranial bleeding Reoperation after closure of the sternotomy incision for the purpose of controlling bleeding Transfusion of ≥5 U PRBCs or whole blood within a 48-h period; cell saver transfusion will not be counted in calculations of blood products. Chest tube output >2 L within a 24-h period

”